Nanjing ChomiX Biotech Co., Ltd. is a pioneered company focused on removing the boundaries of druggability to enable breakthrough medicines for patients with cutting-edge chemical proteomics technology. We are focusing on providing target discovery of small molecule drugs (synthetic inhibitors, natural products, metabolites, polypeptide drugs, etc.) for the enterprises and the universities, as well as screening of innovative covalent drug lead compounds.
Since its official launch in July 2021, we have established long-term cooperation with many novel drug R&D enterprises in the field of kinase inhibitors, PROTAC drugs, small molecule discovery of new covalent drugs etc. At present, a technical team of chemical proteomics professionals from Peking University, Nanjing University, Chinese Academy of Sciences, and other universities is formed.
With profound experience in chemical probe design, synthesis and target discovery, we provide one-stop service for the customers on target discovery and leading compound screening. Chomix Biotech actively responds to the call of the country, leads the development trend of science and technology, gathers talents from all over the world with an inclusive mind. We also would like to promote the cross integration of chemical, biological and medical research as our own responsibility, and upholds the "talent first, innovation first, customer first" as values and strive to become a world-renowned innovative R&D enterprise.
Colossal Biosciences will always guide the development of the company with a pragmatic, rigorous, and pursuit of excellence scientific research spirit, adhere to "talent first, technology first, customer first", and use advanced technology to solve problems for customers and create value. Only by being down-to-earth can we look up at the stars. Colosse Bio will continue to research and develop its own core technology, and strive to always remain the number one on the track and lead the development of the industry.